Adc Therapeutics SA Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)1.52 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $1.22Price as of 30 Sep 2026 Data confidenceNot applicable Market Cap $155.8M Enterprise Value −$57.2M Shares Outstanding 127.7M diluted Next Earnings Date31 Dec 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary ADC Therapeutics SA (ADCT) is a commercial-stage pioneer in antibody-drug conjugates (ADCs), anchored by its FDA-approved product ZYNLONTA. While the company recently achieved a major milestone with its Phase 3 LOTIS-5 confirmatory trial meeting its primary endpoint of progression-free survival (PFS), significant safety concerns have emerged. Specifically, the trial revealed a higher incidence of serious adverse events, treatment-related deaths, and treatment discontinuations in the ZYNLONTA arm, particularly among patients aged 75 years or older. This safety profile introduces substantial regulatory risk as the company prepares for its pre-sBLA meeting in August 2026 and planned sBLA submission in Q4 2026. Although the company maintains a solid cash runway extending into 2028, the near-term stock performance will be heavily dictated by how the FDA weighs the positive efficacy outcomes against these safety signals. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$2.00 Mean target$5.00 High · most bullish analyst$10.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The FDA raises critical safety objections during the regulatory review of the LOTIS-5 data, leading to a refusal to file or a Complete Response Letter (CRL). This delays or derails the 2L+ expansion, forcing the company to rely solely on the slow-growing 3L+ market, accelerating cash burn and increasing dilution risk. Base CaseCentral scenario The FDA accepts the sBLA for ZYNLONTA plus rituximab in 2L+ DLBCL but imposes strict black-box warnings or restricted labeling for elderly patients (75+). ZYNLONTA continues its steady commercial trajectory in 3L+ DLBCL, and the company successfully manages its cash runway into 2028 through disciplined spending. Bull CaseUpside scenario Successful label expansion of ZYNLONTA into earlier lines of therapy (e.g., second-line DLBCL via LOTIS-5 confirmatory trial) and combination regimens (e.g., LOTIS-7), which could double the addressable patient population and unlock potential U.S. peak annual revenues of $600 million to $1 billion. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |